DAYBU® by the European Commission, including the potential timing of such approval, and if approved, the potential benefits of trofinetide as a treatment of the neurobehavioral symptoms of Rett Syndrome and the importance of trofinetide to patients, caregivers and the Rett community. Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements. Such risks, uncertainties and other factors include, but are not limited to, the inherent uncertainty regarding development of product candidates, including approval of trofinetide by the European Commission; our dependency on the continued successful commercialization of our products and our ability to maintain or increase sales of our products; our ability to obtain necessary regulatory approvals to commercialize our products
=*=*=*=*=*=
当前为第7/10页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页